Full text is available at the source.
Randomized Trial Links Time of Day to Immunotherapy Success
Time of day may affect how well immunotherapy works, based on a randomized trial
AI simplified
Abstract
Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer.
- This finding is based on the first randomized trial that examined the timing of immunotherapy.
- Aligning cancer treatment with circadian biology may enhance patient outcomes.
- The results suggest a potential strategy to improve survival rates in this patient population.
AI simplified